Validation of an Interval Test for Monitoring Cardiovascular Function for Individuals with Different Levels of Physical Fitness

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

In this study, investigators will use the IFT 30-15 test, a six-minute walking test, and a treadmill test to assess the participants' cardiorespiratory fitness. For the treadmill cardiopulmonary exercise test (CPET), we will measure indirect gas exchange using a CPET device (K5). Maximum heart rate (HRmax) will be measured with a Polar heart rate monitor (model H10). The six-minute walking test will follow standardized procedures, and the treadmill test will follow a protocol of gradually increasing speed each minute. The study will involve two groups of participants: healthy individuals and pre-hypertensive individuals. While the IFT 30-15 test has been validated on a diverse range of athletes and physically active individuals, it has not yet been validated in individuals with similar characteristics to our participants (BMI \> 30 and limited cardiovascular function). Additionally, a variety of hemodynamic measures and other physical function measures such as sit-to-stand and push-ups will be assessed for all participants.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Adults (18 + years of age) without restriction on sex, health status or physical fitness.

Locations
Other Locations
Slovenia
Faculty of Sport, University of Ljubljana
RECRUITING
Ljubljana
Contact Information
Primary
Armin H Researcher, PhD
armin.paravlic@fsp.uni-lj.si
+386015207840
Backup
Kristina Drole, MSc
Kristina.Drole@fsp.uni-lj.si
Time Frame
Start Date: 2024-11-04
Estimated Completion Date: 2027-10-30
Participants
Target number of participants: 30
Treatments
Asymptomatic individuals - apparently healthy
Asymptomatic individuals - apparently healthy
Symptomatic individuals
Symptomatic individuals - prehypertensive and hypertensive individuals
Related Therapeutic Areas
Sponsors
Leads: University of Ljubljana

This content was sourced from clinicaltrials.gov